Loading...
Market
Will AlphaProteo be used to develop a new drug that enters clinical trials by September 5, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Clinical trial registries and announcements from pharmaceutical companies
Story
Google DeepMind Unveils AlphaProteo with 3-300x Better Protein Design
Sep 5, 2024, 03:53 PM
Google DeepMind has announced AlphaProteo, a new machine learning system designed to create high-affinity protein binders. AlphaProteo achieves binding affinities and success rates that are 3-300 times better compared to existing methods. The system aims to unlock the design of proteins for challenging and impactful biology problems. However, some researchers have expressed disappointment over the lack of methodological details in DeepMind's white paper on AlphaProteo. The white paper indicates that AF3 is better than AF2 for filtering de novo designed binders.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
0-1 • 25%
2-3 • 25%
4-5 • 25%
More than 5 • 25%
Drug Development • 25%
Disease Diagnosis • 25%
Biosensor Technology • 25%
Other • 25%
Cancer • 25%
Autoimmune disorders • 25%
Infectious diseases • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Yes • 50%
No • 50%
Cancer • 25%
Neurodegenerative Diseases • 25%
Cardiovascular Diseases • 25%
Other • 25%